Evidence map›Paper›PMID 36732762›Full record

ReviewCancer cell international2023

A review on the role of long non-coding RNA and microRNA network in clear cell renal cell carcinoma and its tumor microenvironment.

Qi Zhang, Hao Ren, Luqi Ge, Wen Zhang, Feifeng Song, Ping Huang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Establishment of a Seven-Gene Signature Associated with CD8International journal of molecular sciences · 2023
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Expression and prognostic significance of CRKL in clear cell renal cell carcinoma.American journal of clinical and experimental immunology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Long noncoding RNATranslational andrology and urology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qi ZhangDepartment of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Hao RenDepartment of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Luqi GeDepartment of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Wen ZhangDepartment of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Feifeng SongCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. songfeifeng@hmc.edu.cn.
Ping HuangCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. huangping@hmc.edu.cn.
Hangzhou Medical College · CNZhejiang Provincial People's Hospital · CNZhejiang University of Technology · CN

Funding

Leading Talent of "Ten Thousand Plan" - National High-Level Talents Special Support Plan and the Science Technology Plan Project of Zhejiang Province No. 2020R52029Medical and Health Research Program of Zhejiang No. 2021KY046National Natural Science Foundation of China No. 82003853Zhejiang Province Natural Science Foundation of China No. LYY21H310009
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is the second lethal urogenital malignancy with the increasing incidence and mortality in the world. Clear cell renal cell carcinoma (ccRCC) is one major subtype of RCC, which accounts for about 70 to 80% of all RCC cases. Although many innovative therapeutic options have emerged during the last few decades, the efficacy of these treatments for ccRCC patients is very limited. To date, the prognosis of patients with advanced or metastatic ccRCC is still poor. The 5-year survival rate of these patients remains less than 10%, which mainly attributes to the complexity and heterogeneity of the tumor microenvironment (TME). It has been demonstrated that long non-coding RNAs (lncRNAs) perform an indispensable role in the initiation and progression of various tumors. They mostly function as sponges for microRNAs (miRNAs) to regulate the expression of target genes, finally influence the growth, metastasis, apoptosis, drug resistance and TME of tumor cells. However, the role of lncRNA/miRNA/mRNA axis in the TME of ccRCC remains poorly understood. In this review, we summarized the biological function of lncRNA/miRNA/mRNA axis in the pathogenesis of ccRCC, then discussed how lncRNA/miRNA/mRNA axis regulate the TME, finally highlighted their potential application as novel biomarkers and therapeutic targets for ccRCC.

Indexed as

Clear cell renal cell carcinomalncRNAmiRNARegulatory networkTME

Identifiers

PMID36732762
PMCPMC9893571
OpenAlexW4319043513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.